Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. (Q38449826)
Jump to navigation
Jump to search
scientific article published on 17 June 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. |
scientific article published on 17 June 2013 |
Statements
Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study (English)
Diana Bonderman
Stephan B Felix
Evangelos Michelakis
Veselin Mitrovic
Ronald J Oudiz
Francis Boateng
Andrea-Viviana Scalise
Lothar Roessig
Marc J Semigran
Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial (LEPHT) Study Group